HC Wainwright Reaffirms Buy Rating for Faeth Therapeutics
HC Wainwright maintains its buy rating on Faeth Therapeutics with a $60 price target, a 144.50% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for Faeth Therapeutics, Inc. (FTH) with a $60 price target on June 22, 2026.
- HC Wainwright's $60 price target implies 144.50% upside from Faeth Therapeutics, Inc.'s ($FTH) current $24.54 share price.
- Faeth Therapeutics, Inc. is a biotechnology company focused on cancer therapeutics, trading at $17.82 on Tuesday.
- The company has a market cap of $597.8 million, with a strong buy consensus and a target mean price of $52.5 from four analysts.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright reaffirmed its buy rating for Faeth Therapeutics, Inc. (NasdaqCM: FTH) on June 22, 2026, maintaining a price target of $60. This reiteration comes as the company continues its focus on developing cancer therapeutics.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Faeth Therapeutics, Inc. Stock Down 27.5%
Shares of NasdaqCM:FTH traded near $17.82 on Tuesday. Faeth Therapeutics, Inc. has a market cap of approximately $597.8 million and a beta of -0.231, indicating lower volatility compared to the market. The stock has seen a 52-week low of $6.33 and a high of $36.76. Its 50-day moving average is $22.11, while the 200-day moving average stands at $16.41. The company boasts a strong current ratio of 14.39 and a quick ratio of 14.29.
$FTH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its buy rating for Faeth Therapeutics with a price target of $60. The consensus among analysts is a strong buy, with a target mean price of $52.5, derived from four analyst opinions.
About Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland. It specializes in discovering and developing therapeutics for cancer patients. The company's key products include PIKTOR, an investigational inhibitor for endometrial and breast cancer, and Solnerstotug, a monoclonal antibody in clinical trials targeting solid tumors. Faeth's pipeline also includes early-stage antibodies SNS-102 and SNS-103, and SNS-201, a bispecific antibody targeting CD28. Originally known as Sensei Biotherapeutics, Inc., the company rebranded to Faeth Therapeutics in June 2026.
Bottom Line
HC Wainwright's reaffirmation of a buy rating for Faeth Therapeutics underscores confidence in the company's prospects. Investors closely follow such analyst ratings to gauge market sentiment and potential future performance. As a reminder, these ratings are based on past data and do not necessarily reflect current positions or future outcomes.
Get Faeth Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $FTH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.